Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,204
archived clinical trials in
Healthy Studies

Reduce African-American Infant Mortality
Randomized Messaging Trial to Reduce African-American Infant Mortality
Status: Enrolling
Updated:  12/18/2015
MedStar Washington Hospital Center
mi
from
Washington,
Reduce African-American Infant Mortality
Randomized Messaging Trial to Reduce African-American Infant Mortality
Status: Enrolling
Updated: 12/18/2015
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects
A Pilot Study to Characterize Adipose Tissue Leukocytes by Flow Cytometry and Microscopy in Lean, Obese and Psoriatic Subjects (Lean/Obese)
Status: Enrolling
Updated:  12/18/2015
Rockefeller University
mi
from
New York, NY
Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects
A Pilot Study to Characterize Adipose Tissue Leukocytes by Flow Cytometry and Microscopy in Lean, Obese and Psoriatic Subjects (Lean/Obese)
Status: Enrolling
Updated: 12/18/2015
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
Working Memory Changes With Aging and Hearing Loss
Effects of Aging and Hearing Loss During Rapid Sound Processing
Status: Enrolling
Updated:  12/21/2015
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Working Memory Changes With Aging and Hearing Loss
Effects of Aging and Hearing Loss During Rapid Sound Processing
Status: Enrolling
Updated: 12/21/2015
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Click here to add this to my saved trials
Effects of Pioglitazone on Platelet Function
Effects of Pioglitazone on Platelet Function
Status: Enrolling
Updated:  12/23/2015
University of Rochester
mi
from
Rochester, NY
Effects of Pioglitazone on Platelet Function
Effects of Pioglitazone on Platelet Function
Status: Enrolling
Updated: 12/23/2015
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of KBP-7072
A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-7072 Following Oral Administration
Status: Enrolling
Updated:  12/28/2015
KBP
mi
from
Princeton, NJ
Safety, Tolerability and Pharmacokinetics of KBP-7072
A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-7072 Following Oral Administration
Status: Enrolling
Updated: 12/28/2015
KBP
mi
from
Princeton, NJ
Click here to add this to my saved trials
Study of Single Doses of IV Aerucin in Healthy Adults
A Phase 1 Single-center (U.S.), Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of Single Doses of Intravenous AerucinTM in Healthy Adult Subjects
Status: Enrolling
Updated:  12/28/2015
SNBL-CPC
mi
from
Baltimore, MD
Study of Single Doses of IV Aerucin in Healthy Adults
A Phase 1 Single-center (U.S.), Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of Single Doses of Intravenous AerucinTM in Healthy Adult Subjects
Status: Enrolling
Updated: 12/28/2015
SNBL-CPC
mi
from
Baltimore, MD
Click here to add this to my saved trials
Does Sweet Taste Potentiate Nicotine Cue Reactivity?
Does Sweet Taste Potentiate Nicotine Cue Reactivity?
Status: Enrolling
Updated:  12/28/2015
John B. Pierce Laboratory
mi
from
New Haven, CT
Does Sweet Taste Potentiate Nicotine Cue Reactivity?
Does Sweet Taste Potentiate Nicotine Cue Reactivity?
Status: Enrolling
Updated: 12/28/2015
John B. Pierce Laboratory
mi
from
New Haven, CT
Click here to add this to my saved trials
Increase Breastfeeding Duration Among Puerto Rican Mothers
Intervention to Increase Breastfeeding Duration Among Puerto Rican Mothers
Status: Enrolling
Updated:  1/6/2016
Special Supplemental Nutrition Program for Women, Infants, and Children
mi
from
Philadelphia, PA
Increase Breastfeeding Duration Among Puerto Rican Mothers
Intervention to Increase Breastfeeding Duration Among Puerto Rican Mothers
Status: Enrolling
Updated: 1/6/2016
Special Supplemental Nutrition Program for Women, Infants, and Children
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Body Composition Methodology in Young Children (InfantPod)
Development of a Body Composition Method for Infants and Children
Status: Enrolling
Updated:  1/6/2016
Arkansas Children's Nutrition Center
mi
from
Little Rock, AR
Study of Body Composition Methodology in Young Children (InfantPod)
Development of a Body Composition Method for Infants and Children
Status: Enrolling
Updated: 1/6/2016
Arkansas Children's Nutrition Center
mi
from
Little Rock, AR
Click here to add this to my saved trials
Sleep, Mood, and Behavior Study
Sleep, Mood, and Behavior Study:Transdisciplinary Studies of CBT for Anxiety in Youth
Status: Enrolling
Updated:  1/6/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Sleep, Mood, and Behavior Study
Sleep, Mood, and Behavior Study:Transdisciplinary Studies of CBT for Anxiety in Youth
Status: Enrolling
Updated: 1/6/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety Study of CD24Fc When Administered Intravenously in Healthy Adult Subjects
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CD24Fc When Administered Intravenously in Healthy Adult Subjects
Status: Enrolling
Updated:  1/6/2016
Medpace Clinical Pharmacology Unit (CPU)
mi
from
Cincinnati, OH
Safety Study of CD24Fc When Administered Intravenously in Healthy Adult Subjects
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CD24Fc When Administered Intravenously in Healthy Adult Subjects
Status: Enrolling
Updated: 1/6/2016
Medpace Clinical Pharmacology Unit (CPU)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
A Phase I Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered BPM 31510 in Healthy Subjects
Status: Enrolling
Updated:  1/7/2016
Clinilabs, Inc.
mi
from
Eatontown, NJ
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
A Phase I Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered BPM 31510 in Healthy Subjects
Status: Enrolling
Updated: 1/7/2016
Clinilabs, Inc.
mi
from
Eatontown, NJ
Click here to add this to my saved trials
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
Vaccination Response Following Administration of Ixekizumab to Healthy Subjects
Status: Enrolling
Updated:  1/7/2016
Covance, Inc.
mi
from
Daytona Beach, FL
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
Vaccination Response Following Administration of Ixekizumab to Healthy Subjects
Status: Enrolling
Updated: 1/7/2016
Covance, Inc.
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
Vaccination Response Following Administration of Ixekizumab to Healthy Subjects
Status: Enrolling
Updated:  1/7/2016
Covance
mi
from
Evansville, IN
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
Vaccination Response Following Administration of Ixekizumab to Healthy Subjects
Status: Enrolling
Updated: 1/7/2016
Covance
mi
from
Evansville, IN
Click here to add this to my saved trials
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
Vaccination Response Following Administration of Ixekizumab to Healthy Subjects
Status: Enrolling
Updated:  1/7/2016
Covance, Inc.
mi
from
Dallas, TX
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
Vaccination Response Following Administration of Ixekizumab to Healthy Subjects
Status: Enrolling
Updated: 1/7/2016
Covance, Inc.
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants
A Study to Investigate the Effect of Increased Gastric pH From the Administration of the Proton Pump Inhibitor (PPI) Rabeprazole on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Subjects
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Overland Park, KA
A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants
A Study to Investigate the Effect of Increased Gastric pH From the Administration of the Proton Pump Inhibitor (PPI) Rabeprazole on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Subjects
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine
Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine
Status: Enrolling
Updated:  1/8/2016
The Mayo Clinic
mi
from
Rochester, MN
Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine
Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine
Status: Enrolling
Updated: 1/8/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Fitness, Cellular Aging, and Caregiver Stress Study
The Effects of Exercise and Life Stress on Telomere Maintenance and Cardiovascular Disease Risk
Status: Enrolling
Updated:  1/11/2016
University of California at San Francisco
mi
from
San Francisco, CA
Fitness, Cellular Aging, and Caregiver Stress Study
The Effects of Exercise and Life Stress on Telomere Maintenance and Cardiovascular Disease Risk
Status: Enrolling
Updated: 1/11/2016
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Improving Consent and Survey Procedures for Young MSM in Web-based HIV Prevention
Improving Consent and Survey Procedures for Young MSM in Web-based HIV Prevention
Status: Enrolling
Updated:  1/13/2016
Rollins School of Public Health, Emory University
mi
from
Atlanta, GA
Improving Consent and Survey Procedures for Young MSM in Web-based HIV Prevention
Improving Consent and Survey Procedures for Young MSM in Web-based HIV Prevention
Status: Enrolling
Updated: 1/13/2016
Rollins School of Public Health, Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation
Phase IV Study of the Effects of Divalproex Sodium on Food Intake and Energy Expenditure.
Status: Enrolling
Updated:  1/15/2016
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation
Phase IV Study of the Effects of Divalproex Sodium on Food Intake and Energy Expenditure.
Status: Enrolling
Updated: 1/15/2016
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants
A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 Abiraterone Acetate Coated Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Uncoated Tablet Formulation Under Fasted Conditions in Healthy Male Subjects
Status: Enrolling
Updated:  1/18/2016
Clinical Research Facility
mi
from
Tempe, AZ
Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants
A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 Abiraterone Acetate Coated Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Uncoated Tablet Formulation Under Fasted Conditions in Healthy Male Subjects
Status: Enrolling
Updated: 1/18/2016
Clinical Research Facility
mi
from
Tempe, AZ
Click here to add this to my saved trials
Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers
An Open-Label, Randomized, Single-Dose, Two-Period, Two-Way Crossover Comparative Bioavailability Study of Dronabinol Oral Solution, 4.25 mg to Marinol Capsule, 5 mg in Healthy Volunteers Under Fed Conditions
Status: Enrolling
Updated:  1/18/2016
Worldwide Clinical Trials Early Phase Services
mi
from
San Antonio, TX
Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers
An Open-Label, Randomized, Single-Dose, Two-Period, Two-Way Crossover Comparative Bioavailability Study of Dronabinol Oral Solution, 4.25 mg to Marinol Capsule, 5 mg in Healthy Volunteers Under Fed Conditions
Status: Enrolling
Updated: 1/18/2016
Worldwide Clinical Trials Early Phase Services
mi
from
San Antonio, TX
Click here to add this to my saved trials
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Status: Enrolling
Updated:  1/19/2016
Indiana Clinical Research Center
mi
from
Indianapolis, IN
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Status: Enrolling
Updated: 1/19/2016
Indiana Clinical Research Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage
Status: Enrolling
Updated:  1/21/2016
Clinical Research Facility
mi
from
Anaheim, CA
A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage
Status: Enrolling
Updated: 1/21/2016
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage
Status: Enrolling
Updated:  1/21/2016
Clinical Research Facility
mi
from
Miami, FL
A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage
Status: Enrolling
Updated: 1/21/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage
Status: Enrolling
Updated:  1/21/2016
Clinical Research Facility
mi
from
Orlando, FL
A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage
Status: Enrolling
Updated: 1/21/2016
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
"ADAPT" The Adaptation to High Fat Diets Extention
ADAPT-The Adaptation to High Fat Diets
Status: Enrolling
Updated:  1/22/2016
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
"ADAPT" The Adaptation to High Fat Diets Extention
ADAPT-The Adaptation to High Fat Diets
Status: Enrolling
Updated: 1/22/2016
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Mechanisms of the Effect of Physical Activity on the Adaptation to a High-Fat Diet
Mechanisms of the Effect of Physical Activity on the Adaptation to a High-Fat Diet
Status: Enrolling
Updated:  1/22/2016
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Mechanisms of the Effect of Physical Activity on the Adaptation to a High-Fat Diet
Mechanisms of the Effect of Physical Activity on the Adaptation to a High-Fat Diet
Status: Enrolling
Updated: 1/22/2016
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Oscillations of Dietary Fat/Carbohydrate Intake Over Interval of 3 to 4 Days
Oscillations in Dietary Fat Intake and Leptin Changes Among People Who Record Dietary Intake Accurately: the Dietitian Study II
Status: Enrolling
Updated:  1/22/2016
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Oscillations of Dietary Fat/Carbohydrate Intake Over Interval of 3 to 4 Days
Oscillations in Dietary Fat Intake and Leptin Changes Among People Who Record Dietary Intake Accurately: the Dietitian Study II
Status: Enrolling
Updated: 1/22/2016
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Coastal Clinical Research Inc
mi
from
Mobile, AL
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Coastal Clinical Research Inc
mi
from
Mobile, AL
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Clinical Research Advantage/Desert Clinical Research, LLC
mi
from
Mesa, AZ
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Clinical Research Advantage/Desert Clinical Research, LLC
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Clinical Research Advantage, Inc./Fiel Family and Sports Medicine, PC
mi
from
Tempe, AZ
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Clinical Research Advantage, Inc./Fiel Family and Sports Medicine, PC
mi
from
Tempe, AZ
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
eStudySite
mi
from
La Mesa, CA
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
eStudySite
mi
from
La Mesa, CA
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Benchmark Research
mi
from
Sacramento, CA
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Benchmark Research
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Broward Research Group
mi
from
Hollyood, FL
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Broward Research Group
mi
from
Hollyood, FL
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Altus Research
mi
from
Lake Worth, FL
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Altus Research
mi
from
Lake Worth, FL
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Miami Research Associates
mi
from
South Miami, FL
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Palm Beach Research Center
mi
from
West Palm Beach, FL
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Palm Beach Research Center
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Johnson County Clin-Trials
mi
from
Lenexa, KA
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Johnson County Clin-Trials
mi
from
Lenexa, KA
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Benchmark Research
mi
from
Metairie, LA
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Benchmark Research
mi
from
Metairie, LA
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Milford Emergency Associates, Inc.
mi
from
Milford, MA
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Milford Emergency Associates, Inc.
mi
from
Milford, MA
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Bellevue Urgent Care
mi
from
Bellevue, NE
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Bellevue Urgent Care
mi
from
Bellevue, NE
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Meridian Clinical Research
mi
from
Bellevue, NE
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Meridian Clinical Research
mi
from
Bellevue, NE
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Pioneer Clinical Research, LLC
mi
from
Bellevue, NE
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Pioneer Clinical Research, LLC
mi
from
Bellevue, NE
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Meridian Clinical Research
mi
from
Omaha, NE
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Meridian Clinical Research
mi
from
Omaha, NE
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Central New York Clinical Research
mi
from
Manlius, NY
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Central New York Clinical Research
mi
from
Manlius, NY
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
PMG Research of Raleigh, LLC
mi
from
Raleigh, NC
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
PMG Research of Raleigh, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated:  1/26/2016
Community Research
mi
from
Cincinnati, OH
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years
Status: Enrolling
Updated: 1/26/2016
Community Research
mi
from
Cincinnati, OH
Click here to add this to my saved trials